NCT03228368

The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients

The Predicted Potential of Quantitative T Cell Repertoire(TCR) Analysis Using Next-generation Sequencing (NGS) in Anti-PD-L1 Treatment in Non Small Cell Lung（NSCLC) Cancer Patients

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 10 (estimated)
• Sponsor: First Affiliated Hospital of Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to evaluate the predicted potential of quantitative T cell repertoire (TCR) of T cell receptor chains using next-generation sequencing (NGS) in the treatment of the anti-programmed death-ligand 1 (PD-L1) antibody atezolizumab in participants with locally advanced or metastatic NSCLC who have progressed during or following a platinum-containing regimen. Treatment may continue until disease progression or unacceptable toxicity.

Conditions

• Non-Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Atezolizumab (MPDL3280A)	anti-programmed death-ligand 1 (PD-L1) antibody

Timeline

• Start date: 2017-03-01
• Primary completion: 2018-03-01
• Completion: 2018-12-01
• First posted: 2017-07-24
• Last updated: 2017-07-24

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study